Category Archives: Mesenchymal Stem Cells

IMAGE:This is the cover for Stem Cells, Tissue Engineering and Regenerative Medicine. view more Credit: World Scientific, 2015 In his latest book published by World Scientific, Professor David Warburton from The Saban Research Institute of Children's Hospital Los Angeles and the University of Southern California presents a collection of essays on the current state of the regenerative medicine and stem cell research field. Entitled Stem Cells, Tissue Engineering and Regenerative Medicine, this up-to-date compendium surveys current issues in stem cell biology and regenerative medicine. Topics range from key concepts in regenerative medicine to the newest progenitor cell therapies for organ systems, to advice on how to set up a pluripotent stem cell laboratory. Overviews of the most recent progress in stem cell research describe work that is in the pre-clinical pipeline from scientists working at The Saban Research Institute of Children's Hospital Los Angeles and colleagues around the world. "The book addresses some of the big questions faced by researchers in the field of stem cell biology and regenerative medicine," said Professor Warburton. "Those of us working in this field in California are positively impacted by the critical funding provided by the citizens of the state through the California Institute … Continue reading →

UC Irvine scientists studying the role of circadian rhythms in skin stem cells found that this clock plays a key role in coordinating daily metabolic cycles and cell division. Their research, which appears Jan. 6 in Cell Reports, shows for the first time how the body's intrinsic day-night cycles protect and nurture stem cell differentiation. Furthermore, this work offers novel insights into a mechanism whereby an out of synch circadian clock can contribute to accelerated skin aging and cancers. Bogi Andersen, professor of biological chemistry and medicine, and Enrico Gratton, professor of biomedical engineering, focused their efforts on the epidermis, the outermost protective layer of the skin that is maintained and healed by long-lived stem cells. While the role of the circadian clock in processes such as sleep, feeding behavior and metabolism linked to feeding and fasting are well known, much less is known about whether the circadian clock also regulates stem cell function. The researchers used novel two-photon excitation and fluorescence lifetime imaging microscopy in Laboratory of Fluorescence Dynamics in UCI's Department of Biomedical Engineering to make sensitive and quantitative measurements of the metabolic state of single cells within the native microenvironment of living tissue. They discovered that the … Continue reading →

Published 07 January 2015 Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS). The FDA orphan drug designation coincides with the positive opinion of the European Medicines Agency's (EMA's) Committee for Orphan Medicinal Products (COMP) regarding NiCord as a treatment for AML. Gamida Cell intends to file for NiCord orphan drug status with the EMA for other indications as well. "Receipt of orphan drug status for NiCord in the US and Europe advances Gamida Cell's commercialization plans a major step further, as both afford significant advantages. We very much appreciate the positive feedback and support of the FDA and EMA and look forward to continuing what has been a very positive dialogue with these important agencies," said Gamida Cell president and CEO Dr. Yael Margolin. The FDA and EMA grant an orphan drug designation to promote the development of products that demonstrate promise for … Continue reading →

Lady Lake, FL (PRWEB) January 06, 2015 Neil Riordan, PhD, co-founder of the Riordan-McKenna Institute, will present The Role of Mesenchymal Stem Cells in the Reversal of Chronic Diseases this Saturday, January 10th at the International Society for the Reversal of Chronic Diseases inaugural symposium: Can Chronic Diseases be Reversed? in Lady Lake, Florida. The symposium will run from 8 a.m. to 4 p.m. at the Harbor Chase Village Crossing assisted living facility on NE 86th Dr. in The Villages across from The Villages Regional Hospital in Lady Lake, Florida 32159. The facility of golf cart accessible and lunch will be served to all attendees. Tickets are $10 per person and RSVP is requires. Attendance is limited to 100 participants. For more information or to purchase tickets, please contact Sheri Tor at 352-323-5506 or email: stor(at)CFHAlliance(dot)org. Credit card payments are accepted. Distinguished guests include: Moderator: Shalesh Kaushal, MD, PhD: Retina Specialty Institute BS: Yale University; MD: John Hopkins; PhD: MIT, with Nobel Laureate Dr. Har Gobind Khorana Caldwell B. Esselstyn Jr., MD, Cleveland Clinic Retired endocrine surgeon and author He and Dr. Colin Campbell recommended a diet adopted by President Bill Clinton. T. Colin Campbell, PhD, Cornell University Jacob Gould … Continue reading →

Turning 10 years old may not quite mark adolescence for a human child, but for a major government research effort such as California's stem cell program, it's well past middle age. So it's a little strange to hear C. Randal Mills, the new president and chief executive of the program known formally as the California Institute for Regenerative Medicine, say it's time to instill in CIRM "a clear sense of mission." But that's what Mills is planning for the coming year, as he launches CIRM 2.0, a comprehensive reboot of the program. Mills, a former biotech company chief executive, took over as CIRM's president last May. His first task, he told me, was to "take a step back and look broadly at how we do our business." He reached the conclusion that "there was a lot of room for improvement." That's a striking admission for a program that already has allocated roughly two-thirds of its original $3-billion endowment. Biomedical researchers are sure to find a lot to like about CIRM 2.0, especially Mills' commitment to streamline the program's grant and loan approval process for projects aimed at clinical trials of potential therapies. Reviews of applications take about 22 months on … Continue reading →

In April of 2013, the results of three clinical trials that examined the effects of bone marrow-derived stem cell treatments in patients with acute myocardial infarction (translation a recent heart attack) or chronic heart failure. These trials were the SWISS-AMI trial, the CELLWAVE trial, and the C-CURE trial. The SWISS-AMI trial (Circulation. 2013;127:1968-1979), which stands for the Swiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction trial, was designed to examine the optimal time of stem cell administration at 2 different time points: early or 5 to 7 days versus late or 3 to 4 weeks after a heart attack. This trial is an extension of the large REPAIR-AMI, which showed that patients who tended to receive bone marrow stem cell treatments later rather than earlier had more pronounced therapeutic effects from the stem cell treatments. SWISS-AMI examined 60 patients who received standard cardiological care after a heart attack, 58 who received bone marrow stem cells 5-7 days after a heart attack, and 49 patients who received bone marrow stem cells 3-4 weeks after their heart attacks. All stem cells were delivered through the coronary arteries by means of the same technology used to deliver a stent. When the … Continue reading →

PLoS ONE : Comparison of Human Induced Pluripotent Stem-Cell Derived Cardiomyocytes with Human... KeSimpulan | Comparison of Human Induced Pluripotent Stem-Cell Derived Cardiomyocytes with Human Mesenchymal Stem Cells following Acute Myocardial Infarction. Lucas Citro et al. (2014), PLoS. By: KeSimpulan … Continue reading →

Chuck Bednar for redOrbit.com Your Universe Online Two-thirds of all adult cancer cases are primarily the result of bad luck, according to the authors of a new study appearing in Fridays edition of the journal Science. Dr. Bert Vogelstein, the Clayton Professor of Oncology at the Johns Hopkins University School of Medicine, and Dr. Cristian Tomasetti, an assistant professor of oncology at the Johns Hopkins University School of Medicine and Bloomberg School of Public Health, developed a statistical model that measured the proportion of cancer incidence across many different tissue types. They found that two-thirds of adult cancer incidence across tissues occur when the random mutations that take place during stem cell division drive cancer through, while the remaining one-third of cases are the result of environmental factors and inherited genes. All cancers are caused by a combination of bad luck, the environment and heredity, and weve created a model that may help quantify how much of these three factors contribute to cancer development, explained Dr. Vogelstein, who is also co-director of the Ludwig Center at Johns Hopkins and an investigator at the Howard Hughes Medical Institute. Cancer-free longevity in people exposed to cancer-causing agents, such as tobacco, is often … Continue reading →

An experimental treatment that uses a patient's own stem cells may offer new hope for people with multiple sclerosis. In a small clinical trial, patients experienced long-term disease remission after undergoing a transplant of their own hematopoietic stem cells. This type of cell is responsible for the formation of blood in the body and are typically derived from bone marrow. The patients also took high-dose immunosuppressive drugs. The paper, published Monday in JAMA Neurology, reports on the third year of a five-year study. A total of 24 patients with active relapsing-remitting MS were enrolled in the trial. With this type of MS, patients have points when their disease is active followed by periods when they do not experience any symptoms. Play Video Dr. Jon LaPook goes inside the trial and approval process for an experimental treatment using stem cells designed to make Multiple Sclerosis pati... The researchers found that nearly 79 percent of the patients who underwent the procedure sustained full neurologic function for the three years following the treatment and symptoms of their disease did not progress. Additionally, patients in that time period did not develop any new lesions related to their disease. More than 90 percent of patients … Continue reading →

Boston, MA (PRWEB) December 23, 2014 Earlier this year in a June 24 international conference presentation, Dr. James L. Sherley, director of the Adult Stem Cell Technology Center, LLC (ASCTC) focused attention on an often overlooked and under appreciated unique property of adult tissue stem cells. His title Asymmetric Self-Renewal by Distributed Stem Cells: Misunderstood in the Past, Important for the Future, embodied the essence of his message to congress participants. He gave the address at the 4th World Congress on Cell Science and Stem Cell Research in Valencia, Spain. The international congress was organized by the Omics Group as a part of its mission to foster the dissemination of leading discoveries and advances in life sciences research. Their posting this month of the slides from Dr. Sherley's June 24 keynote address now provides worldwide open access to life sciences investigators - stem cell biologists in particular - of the concepts that he emphasized. In a 2008 publication [Breast Disease 29, 37-46, 2008], Sherley coined the new term distributed stem cells (DSCs) as a biology-based name for all natural tissue stem cells that are not embryonic in origin. Adult stem cells are included under the DSC heading. DSCs do not … Continue reading →